Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis

Multiple Sclerosis Journal

Volumn 19, Issue 2, 2013, Pages 217-224

  Wood, B ^a   Van Der Mei, I A F ^a   Ponsonby, A L ^c   Pittas, F ^a   Quinn, S ^b   Dwyer, T ^c   Lucas, R M ^d   Taylor, B V ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d The Australian National University   (Australia)

Author keywords

anxiety; concurrence; depression; fatigue; Fatigue Severity Score; Hospital Anxiety and Depression Scale; multiple sclerosis; prevalence; prospective cohort

Indexed keywords

ANTIDEPRESSANT AGENT; IMMUNOMODULATING AGENT;

ADULT; ANXIETY; ARTICLE; COMORBIDITY; DEPRESSION; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FATIGUE SEVERITY SCALE; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PREVALENCE; SEASONAL VARIATION; SEX DIFFERENCE;

EID: 84873662808     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512450351     Document Type: Article

References (41)

1. Chwastiak L, Ehde DM, Gibbons LE, et al. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry. 2002 ; 159: 1862-1868
2. Janssens AC, Buljevac D, van Doorn PA, et al. Prediction of anxiety and distress following diagnosis of multiple sclerosis: a two-year longitudinal study. Mult Scler. 2006 ; 12: 794-801
3. Suh Y, Motl RW, Mohr DC. Physical activity, disability, and mood in the early stage of multiple sclerosis. Disabil Health J. 2010 ; 3: 93-98
4. Iriarte J, Subira ML, Castro P. Modalities of fatigue in multiple sclerosis: correlation with clinical and biological factors. Mult Scler. 2000 ; 6: 124-130
5. Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler. 2007 ; 13: 67-72
6. Stenager EN, Stenager E. Suicide and patients with neurologic diseases. Methodologic problems. Arch Neurol. 1992 ; 49: 1296-1303
7. Sadovnick AD, Eisen K, Ebers GC, et al. Cause of death in patients attending multiple sclerosis clinics. Neurology. 1991 ; 41: 1193-1196
8. Brown RF, Valpiani EM, Tennant CC, et al. Longitudinal assessment of anxiety, depression, and fatigue in people with multiple sclerosis. Psychol Psychother. 2009 ; 82: 41-56
9. Pittas F, Ponsonby AL, van der Mei IA, et al. Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. J Neurol. 2009 ; 256: 577-585
10. Simpson S, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol. 2010 ; 68: 193-203
11. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 ; 50: 121-127
12. Simpson S, Pittas F, van der Mei I, et al. Trends in the epidemiology of multiple sclerosis in Greater Hobart, Tasmania: 1951 to 2009. J Neurol Neurosurg Psychiatry. 2011 ; 82: 180-187
13. Bjelland I, Dahl AA, Haug TT, et al. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002 ; 52: 69-77
14. Honarmand K, Feinstein A. Validation of the Hospital Anxiety and Depression Scale for use with multiple sclerosis patients. Mult Scler. 2009 ; 15: 1518-1524
15. First MD, Spitzer RL, Gibbon M, et al Structured clinical interview for Axis 1 DSM-IV disorders - patient edition, SCID-I/P, Version 2.0. New York State Psychiatric Institute ; 1994 :
16. Diagnostic and statistical manual of mental disorders. 4 th ed. Washington DC: American Psychiatric Association, 1994. Washington DC: American Psychiatric Association ; 1994 :
17. Dahl OP, Stordal E, Lydersen S, et al. Anxiety and depression in multiple sclerosis. A comparative population-based study in Nord-Trondelag County, Norway. Mult Scler. 2009 ; 15: 1495-1501
18. Kilkkinen A, Kao-Philpot A, O'Neil A, et al. Prevalence of psychological distress, anxiety and depression in rural communities in Australia. Aust J Rural Health. 2007 ; 15: 114-119
19. Knippenberg S, Bol Y, Damoiseaux J, et al. Vitamin D status in patients with MS is negatively correlated with depression, but not with fatigue. Acta Neurol Scand. 2011 ; 124: 171-175
20. Feinstein A, O'Connor P, Gray T, et al. The effects of anxiety on psychiatric morbidity in patients with multiple sclerosis. Mult Scler. 1999 ; 5: 323-326
21. Poder K, Ghatavi K, Fisk JD, et al. Social anxiety in a multiple sclerosis clinic population. Mult Scler. 2009 ; 15: 393-398
22. Krupp LB, LaRocca NG, Muir-Nash J, et al. The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989 ; 46: 1121-1123
23. Bakshi R, Shaikh ZA, Miletich RS, et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler. 2000 ; 6: 181-185
24. Tellez N, Rio J, Tintore M, et al. Fatigue in multiple sclerosis persists over time: a longitudinal study. J Neurol. 2006 ; 253: 1466-1470
25. Hadjimichael O, Vollmer T, Oleen-Burkey M. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes. 2008 ; 6: 100
26. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983 ; 33: 1444-1452
27. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology. 2005 ; 64: 1144-1151
28. Di Legge S, Piattella MC, Pozzilli C, et al. Longitudinal evaluation of depression and anxiety in patients with clinically isolated syndrome at high risk of developing early multiple sclerosis. Mult Scler. 2003 ; 9: 302-306
29. Giordano A, Granella F, Lugaresi A, et al. Anxiety and depression in multiple sclerosis patients around diagnosis. J Neurol Sci. 2011 ; 307: 86-91
30. Irvine H, Davidson C, Hoy K, Lowe-Strong A. Psychosocial adjustment to multiple sclerosis: exploration of identity redefinition. Disabil Rehabil. 2009 ; 31: 599-606
31. Parsons HM. What happened at Hawthorne?: New evidence suggests the Hawthorne effect resulted from operant reinforcement contingencies. Science. 1974 ; 183: 922-932
32. Szilasiova J, Krokavcova M, Gdovinova Z, et al. Quality of life in patients with multiple sclerosis in Eastern Slovakia. Disabil Rehabil. 2011 ; 33: 1587-1593
33. Trojan DA, Arnold D, Collet JP, et al. Fatigue in multiple sclerosis: association with disease-related, behavioural and psychosocial factors. Mult Scler. 2007 ; 13: 985-995
34. Koch M, Uyttenboogaart M, van Harten A, et al. Fatigue, depression and progression in multiple sclerosis. Mult Scler. 2008 ; 14: 815-822
35. Wallin MT, Wilken JA, Turner AP, et al. Depression and multiple sclerosis: Review of a lethal combination. J Rehabil Res Dev. 2006 ; 43: 45-62
36. Sepulcre J, Masdeu JC, Goni J, et al. Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways. Mult Scler. 2009 ; 15: 337-344
37. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003 ; 301: 386-389
38. Abelson JL, Curtis GC. Hypothalamic-pituitary-adrenal axis activity in panic disorder. 24-hour secretion of corticotropin and cortisol. Arch Gen Psychiatry. 1996 ; 53: 323-331
39. Gottschalk M, Kumpfel T, Flachenecker P, et al. Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. Arch Neurol. 2005 ; 62: 277-280
40. Miller AH. Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface. Brain Behav Immun. 2009 ; 23: 149-158
41. Flachenecker P, Bihler I, Weber F, et al. Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Mult Scler. 2004 ; 10: 165-169